Knowledge Hub
Understanding CKM Syndrome
Cardiovascular-kidney-metabolic syndrome describes the shared biology linking obesity, diabetes, chronic kidney disease, and cardiovascular disease — and the case for treating them as one continuum.
For decades the heart, the kidneys, and metabolism were managed in separate clinics with separate guidelines. The evidence no longer supports that separation. Excess and dysfunctional adipose tissue drives insulin resistance, chronic inflammation, oxidative stress, and neurohormonal activation; these in turn injure the vasculature, the myocardium, and the glomerulus at the same time. A patient with albuminuria and type 2 diabetes is not a nephrology patient who happens to have diabetes — they are a person living with a single, staged, progressive syndrome.
The American Heart Association formalized this construct as cardiovascular-kidney-metabolic (CKM) syndrome, and subsequent interdisciplinary guidance developed jointly with cardiology, diabetology, and nephrology has translated it into staging, screening, and treatment pathways. The CKM Prevention Society exists to help clinicians and health systems put that framework into everyday practice.
~90%
US adults at stage 1 or above
Population-based CKM staging analyses
1 in 7
Adults worldwide with chronic kidney disease
Most are undiagnosed
20.5M
Annual deaths from cardiovascular disease
Leading global cause of death
800M+
People living with diabetes
Roughly half untreated
Figures are drawn from published population estimates and are provided for orientation; consult the primary sources on our resources page for exact definitions and confidence intervals.
Staging
The Five Stages of CKM Syndrome
Staging turns a diffuse risk conversation into a concrete care plan — and makes regression to a lower stage an explicit therapeutic goal.
| Stage | Description | Typical Findings | Care Emphasis |
|---|---|---|---|
| Stage 0 | No CKM risk factors | Normal body mass index and waist circumference, normal glycemia, blood pressure, and lipids; no evidence of kidney or cardiovascular disease. | Primordial prevention: healthy nutrition, physical activity, sleep, tobacco avoidance; reassess every 3-5 years. |
| Stage 1 | Excess or dysfunctional adiposity | Overweight or obesity, abdominal obesity, or adipose tissue dysfunction with prediabetes; no other metabolic risk factors or established disease. | Healthy lifestyle as first-line therapy, 5-10% weight reduction goals, consider intensive behavioral or pharmacologic weight management; annual screening. |
| Stage 2 | Metabolic risk factors or chronic kidney disease | Hypertension, hypertriglyceridemia, metabolic syndrome, type 2 diabetes, or chronic kidney disease (reduced eGFR and/or albuminuria). | Guideline-directed therapy across all axes — including agents with cardio-renal benefit — plus albuminuria surveillance and risk-factor targets. |
| Stage 3 | Subclinical cardiovascular disease in CKM | Subclinical atherosclerosis or subclinical heart failure, very high predicted cardiovascular risk, or high-risk chronic kidney disease. | Intensification of preventive therapy, consideration of imaging or biomarkers, and coordinated cardiology-nephrology-endocrinology input. |
| Stage 4 | Clinical cardiovascular disease in CKM | Clinical coronary disease, heart failure, stroke, peripheral artery disease, or atrial fibrillation in a person with CKM risk factors; subdivided by kidney failure status. | Disease-specific therapy plus continued CKM risk-factor management, cardiac rehabilitation, and kidney-protective strategies. |
Summarized for educational purposes. Always apply the current full guideline text and local protocols to individual patient care.
Mechanisms
One Syndrome, Four Failing Systems
The interconnections that make integrated management more effective than sequential specialty care.
Dysfunctional Adiposity
Visceral and ectopic fat behaves as an endocrine organ, releasing inflammatory adipokines and free fatty acids that drive insulin resistance.
Kidney Injury
Glomerular hyperfiltration, albuminuria, and tubulointerstitial fibrosis both result from and accelerate cardiometabolic disease.
Myocardial Stress
Hypertension, lipotoxicity, and volume overload produce hypertrophy, diastolic dysfunction, and heart failure with preserved ejection fraction.
Vascular Disease
Endothelial dysfunction and accelerated atherosclerosis link metabolic dysregulation to infarction, stroke, and limb ischemia.
Social Drivers
Food access, housing, income, and health-system access shape risk as powerfully as biology and must be measured alongside it.
Care Fragmentation
Siloed follow-up delays albuminuria testing and under-uses therapies with proven cross-axis benefit.
Assessment
A Practical CKM Work-Up
What a complete baseline assessment looks like in primary care and specialty clinics alike.
- Body mass index and waist circumference, recorded at every routine visit
- Blood pressure with correct technique, confirmed out of office where feasible
- Fasting lipid panel including non-HDL cholesterol and triglycerides
- HbA1c or fasting glucose to identify prediabetes and diabetes
- Serum creatinine with estimated glomerular filtration rate (cystatin C when confirmation is needed)
- Urine albumin-to-creatinine ratio — the most frequently missed test in CKM care
- Hepatic steatosis assessment where metabolic dysfunction-associated steatotic liver disease is suspected
- 10- and 30-year total cardiovascular risk estimation using PREVENT
- Social drivers of health screening: food security, medication affordability, housing stability
- Review of sleep, physical activity, tobacco and alcohol use, and mental health
Management
Therapies That Work Across Axes
The modern armamentarium increasingly treats the syndrome rather than a single organ.
- Structured lifestyle therapy: nutrition quality, 150+ minutes of weekly activity, sleep and stress care
- SGLT2 inhibitors for combined cardiac, kidney, and metabolic protection
- GLP-1 and dual incretin receptor agonists for weight, glycemia, and cardiovascular outcomes
- Non-steroidal mineralocorticoid receptor antagonists for albuminuric kidney disease
- Renin-angiotensin system blockade titrated to maximal tolerated dose
- Statins and, when indicated, ezetimibe or PCSK9-directed therapy for lipid targets
- Blood pressure control with combination therapy and home monitoring
- Metabolic and bariatric procedures for eligible patients with severe obesity
- Cardiac rehabilitation and supervised exercise after events
- Team-based follow-up: pharmacy, nursing, dietetics, and community health workers
FAQ
Common Questions About CKM
What is CKM syndrome?
Cardiovascular-kidney-metabolic (CKM) syndrome is a health disorder defined by the American Heart Association describing the connections between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. It reflects shared pathophysiology — excess and dysfunctional adipose tissue, insulin resistance, inflammation, oxidative stress, and neurohormonal activation — rather than four unrelated diagnoses.
How many stages of CKM syndrome are there?
Five: stage 0 (no risk factors), stage 1 (excess or dysfunctional adiposity), stage 2 (metabolic risk factors such as hypertension, hypertriglyceridemia, diabetes, or chronic kidney disease), stage 3 (subclinical cardiovascular disease or very high predicted risk), and stage 4 (clinical cardiovascular disease), with stage 4 subdivided by the presence or absence of kidney failure.
Can CKM syndrome be reversed?
Regression between stages is possible, particularly in earlier stages. Weight management, blood pressure and glycemic control, lipid lowering, smoking cessation, physical activity, and modern cardio-renal-metabolic therapies can move patients back toward lower-risk stages and reduce events.
Who should be screened, and how often?
Contemporary guidance supports routine assessment of blood pressure, body mass index or waist circumference, lipids, glycemia, and kidney function including estimated glomerular filtration rate and urine albumin-to-creatinine ratio for adults, with frequency increasing as CKM stage advances.
What are the PREVENT equations?
PREVENT (AHA Predicting Risk of CVD Events) is a set of sex-specific, race-free equations that estimate 10- and 30-year risk of total cardiovascular disease — atherosclerotic disease plus heart failure — in adults aged 30 to 79. They include estimated glomerular filtration rate and can incorporate urine albumin-to-creatinine ratio, HbA1c, and a social deprivation index.
Why does CKM require interdisciplinary care?
The same patient is often seen separately by primary care, cardiology, nephrology, and endocrinology. Fragmented care delays albuminuria testing, under-uses guideline-directed therapy, and misses opportunities for prevention. Interdisciplinary pathways close those gaps.
Put It Into Practice
Bring CKM Staging to Your Clinic
Members receive curriculum materials, case rounds, and implementation tools as they are released.